← All trials
NCT05986591
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Aug 14, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 335
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ExeltisLead sponsor
- Iberica Co. Ltd.Collaborator
- ExeltisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.